Clinical Trial Update: A Randomised Single Centre Study to Compare the Long-term Performance of 4 Designs of the DePuy Ultima LX Stem in Primary Total Hip Replacement [Phase 3]

View source ↗

Summary

A Phase 3 randomized, single-centre study comparing four designs of the DePuy Ultima LX stem in primary total hip replacement; the trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avascular Necrosis
• Collagen Disorders
• Developmental Dysplasia of the Hip
• Nonunion of Femoral Fractures
• Osteoarthritis
• Post-traumatic Arthritis
• Slipped Capital Femoral Epiphysis
• Traumatic Femoral Fractures

Drugs mentioned

• DePuy Ultima LX Stem

Snippet

Sponsor: DePuy International | Conditions: Osteoarthritis, Post-traumatic Arthritis | Phase 3 | Status: TERMINATED